

## COMMENTARY

# Dysnatraemia and mortality: do sweat the small stuff...

John R Klinck<sup>1</sup>, Lisa McNeill<sup>2,3</sup> and David K Menon<sup>1,2,\*</sup>

See related research by Darmon *et al.*, <http://ccforum.com/content/17/1/R12>

### Abstract

Marked dysnatraemia is associated with increased mortality in patients admitted to intensive care. However, new evidence suggests that even mild deviations from normal and simple variability of sodium values may also be significant. Should these findings prompt clinicians to re-evaluate the approach to fluid management in this setting? Sodium disorders, on one hand, are known to result from overzealous administration or restriction of free water or sodium ions. However, they are also associated with a range of co-morbidities and drug treatments that alter water loss and sodium handling in the nephron independently of prescribed fluid regimens. Moreover, powerful neuroendocrine and inflammatory responses to surgery, trauma and other acute illness may induce or intensify such changes, altering the response to administered fluids. These observations suggest that both patient and treatment variables contribute, but the extent to which sodium disturbances are preventable and whether prevention improves outcome are unknown. Dysnatraemia certainly reflects underlying systemic disorders, but how important is fluid management as a cause, and does it contribute independently to poorer outcomes through osmotic or other mechanisms? Although total fluid volume and doses of potassium and glucose are regularly adjusted in critically ill patients, sodium is usually delivered at standard concentrations as long as serum values lie within an acceptable range. It may be prudent to pay closer attention to these values, especially when abnormal, when fluctuating or when an adverse trend is present. More frequent measurements of sodium in blood, urine and drainage fluids, and appropriate adjustment of the sodium content of prescribed fluids, may be indicated. Until more light can be shed on the pathophysiology of dysnatraemia in the critically ill, we should assume that better control of plasma sodium levels may yield better outcomes.

Moderate-to-severe dysnatraemia has long been recognized as a marker of acuity and mortality risk in the critically ill patient. However, accumulating evidence, including the work of Darmon and colleagues in the previous issue of *Critical Care* [1], suggests that even mild abnormalities of serum sodium concentration present on ICU admission predict increased 30-day mortality. Other recent work indicates that even variability of sodium concentrations, including changes within the normal range, is linked to an increased risk of death [2]. How should the clinician respond to these findings? Does normalization or stabilization of serum sodium values improve outcomes? Will control of serum sodium be the

next important quality measure in the critical care setting [3]?

First, a note of caution. Large observational studies, made possible by growth of critical care services, multi-center collaborations and electronic capture of huge quantities of data, are ever more able to identify predictive effects from subtle changes in laboratory and physiological parameters. In the case of serum electrolytes, however, unmeasured confounders such as blood glucose and disparate or imprecise laboratory assays may become important when small changes are evaluated. Frequency of measurement, naturally higher in sicker patients, is another potential source of bias. It is important not to over-interpret these findings in assessing prognosis and in pursuing interventions. Note that the predictive impact of sodium values near the limits of the normal range in the study from Darmon and colleagues [1] did not achieve statistical significance. On the other hand, the adverse prognostic significance of even modest deviations from the normal range is clear

\*Correspondence: [dkm13@wbic.cam.ac.uk](mailto:dkm13@wbic.cam.ac.uk)

<sup>2</sup>Division of Anaesthesia, University of Cambridge, Box 93, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK

Full list of author information is available at the end of the article

[4]. What cannot be determined from existing studies is the extent to which these dysnatraemias are preventable, and whether prevention or correction improves outcome.

That sodium disorders caused by iatrogenic free water excess and loss are preventable is self-evident. However, it is also clear that these disorders are associated with a range of co-morbidities and drug treatments that alter water loss and sodium retention in the nephron independently of fluid replacement, and that processes distinct from the consequent electrolyte abnormalities may be responsible for biological effects. In patients presenting to the ICU, dysnatraemias are often associated with powerful hormonal responses to injury and inflammation, with effects on osmotic and non-osmotic regulation of antidiuretic hormone [5] (causing a syndrome of inappropriate antidiuresis), the renin-angiotensin-aldosterone axis [6], and the release of natriuretic peptides [7]. Yet little is known about how these responses are altered by administration of fluids, or how changes in sodium concentration might be anticipated from clinically measurable parameters.

Although doses of potassium, glucose and even water are regularly adjusted, sodium is usually delivered at standard concentrations as long as serum values lie within an acceptable range. This is routine practice in renal replacement therapies, and in many ICU patients, with little consideration of the last-recorded sodium measurement or of easily measured sodium losses in urine and drains. While this is well tolerated in most individuals, in some the sodium content of prescribed fluids may be poorly matched to their intravascular volume and neuroendocrine condition, leading to a failure of sodium homeostasis. Until dysnatraemia is shown to be a non-causal biomarker of a harmful underlying systemic process [6], it may be prudent to assume that even modest sodium fluctuations and attendant osmotic shifts are inherently undesirable, and that refined control of plasma sodium levels offers scope for better outcomes.

To minimize this iatrogenic element, to define appropriate therapies and to confirm their beneficial effects, several key investigative and therapeutic steps are needed. Measurements of both serum sodium and of sodium ions lost from the body need to be performed

more frequently, especially when an abnormal serum concentration or adverse trends are present. Detailed data on risk-associated conditions and linked fluid and pharmacologic interventions should be collected and analyzed to inform the development of more sophisticated, individualized fluid regimes. Finally, these more tailored regimes should be tested in randomized trials. Only such studies can conclusively show whether mild dysnatraemia is a remediable contributor to mortality risk, or a marker of impaired neuroendocrine homeostasis, insensitive to treatment and predisposing to allied causes of organ failure and death.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Directorate of Perioperative Care, Box 93, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. <sup>2</sup>Division of Anaesthesia, University of Cambridge, Box 93, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. <sup>3</sup>Department of Public Health, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK.

Published: 2 April 2013

#### References

1. Darmon M, Diconne E, Souweine B, Ruckly S, Adrie C, Azoulay E, Clec'h C, Garrouste-Orgeas M, Schwebel C, Goldgran-Toledano D, Khallel H, Dumenil AS, Jamali S, Cheval C, Allaouchiche B, Zeni F, Timsit JF: **Prognostic consequences of borderline dysnatremia: pay attention to minimal sodium change.** *Crit Care* 2013, **17**:R12.
2. Sakr Y, Rother S, Ferreira AM, Ewald C, Dunisch P, Riedemann N, Reinhart K: **Fluctuations in serum sodium level are associated with an increased risk of death in surgical ICU patients.** *Crit Care Med* 2013, **41**:133-142.
3. Peruzzi W: **Sodium balance: the next core measure?** *Crit Care Med* 2013, **41**:351-352.
4. Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, Metnitz PG: **Incidence and prognosis of dysnatremias present on ICU admission.** *Intensive Care Med* 2010, **36**:304-311.
5. Russell JA: **Bench-to-bedside review: Vasopressin in the management of septic shock.** *Crit Care* 2011, **15**:226.
6. Doerschug KC, Delsing AS, Schmidt GA, Ashare A: **Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis.** *Crit Care* 2010, **14**:R24.
7. Wang F, Wu Y, Tang L, Zhu W, Chen F, Xu T, Bo L, Li J, Deng X: **Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis.** *Crit Care* 2012, **16**:R74.

doi:10.1186/cc12560

**Cite this article as:** Klinck JR, et al.: Dysnatraemia and mortality: do sweat the small stuff... *Critical Care* 2013, **17**:128.

RESEARCH

Open Access

# Prognostic consequences of borderline dysnatremia: pay attention to minimal serum sodium change

Michael Darmon<sup>1\*</sup>, Eric Diconne<sup>1</sup>, Bertrand Souweine<sup>2</sup>, Stéphane Ruckly<sup>3,4</sup>, Christophe Adrie<sup>5</sup>, Elie Azoulay<sup>6</sup>, Christophe Clec'h<sup>7</sup>, Maïté Garrouste-Orgeas<sup>8</sup>, Carole Schwebel<sup>4</sup>, Dany Goldgran-Toledano<sup>9</sup>, Hatem Khallel<sup>10</sup>, Anne-Sylvie Dumenil<sup>11</sup>, Samir Jamali<sup>12</sup>, Christine Cheval<sup>13</sup>, Bernard Allaouchiche<sup>14</sup>, Fabrice Zeni<sup>1</sup> and Jean-François Timsit<sup>3,4</sup>

## Abstract

**Introduction:** To assess the prevalence of dysnatremia, including borderline changes in serum sodium concentration, and to estimate the impact of these dysnatremia on mortality after adjustment for confounders.

**Methods:** Observational study on a prospective database fed by 13 intensive care units (ICUs). Unselected patients with ICU stay longer than 48 h were enrolled over a 14-year period were included in this study. Mild to severe hyponatremia were defined as serum sodium concentration < 135, < 130, and < 125 mmol/L respectively. Mild to severe hypernatremia were defined as serum sodium concentration > 145, > 150, and > 155 mmol/L respectively. Borderline hyponatremia and hypernatremia were defined as serum sodium concentration between 135 and 137 mmol/L or 143 and 145 respectively.

**Results:** A total of 11,125 patients were included in this study. Among these patients, 3,047 (27.4%) had mild to severe hyponatremia at ICU admission, 2,258 (20.3%) had borderline hyponatremia at ICU admission, 1,078 (9.7%) had borderline hypernatremia and 877 (7.9%) had mild to severe hypernatremia. After adjustment for confounder, both moderate and severe hyponatremia (subdistribution hazard ratio (sHR) 1.82, 95% CI 1.002 to 1.395 and 1.27, 95% CI 1.01 to 1.60 respectively) were associated with day-30 mortality. Similarly, mild, moderate and severe hypernatremia (sHR 1.34, 95% CI 1.14 to 1.57; 1.51, 95% CI 1.15 to 1.99; and 2.64, 95% CI 2.00 to 3.81 respectively) were independently associated with day-30 mortality.

**Conclusions:** One-third of critically ill patients had a mild to moderate dysnatremia at ICU admission. Dysnatremia, including mild changes in serum sodium concentration, is an independent risk factor for hospital mortality and should not be neglected.

## Introduction

Dysnatremia is a common finding at ICU admission [1-3]. Abnormal serum sodium concentrations are known to adversely affect physiologic function and an increasing body of evidence suggests that dysnatremia may be associated with adverse outcome [1-4]. Critically ill patients are particularly exposed to dysnatremia due

to the nature of the disease leading to ICU admission and to lack of free access to water [2,4,5]. Up to one-third of critically ill patients have a dysnatremia at ICU admission [2]. In addition, another one-third of critically ill patients will develop an ICU-acquired dysnatremia during ICU stay [4,6]. Prevalence of dysnatremia at ICU admission, however, varies greatly according to the chosen definition [1,2,7,8].

Doubts exist regarding prognostic impact of borderline changes in serum sodium concentration. Serum sodium concentration is closely regulated and physiological serum sodium concentration ranges between 138 and

\* Correspondence: [michael.darmon@chu-st-etienne.fr](mailto:michael.darmon@chu-st-etienne.fr)

<sup>1</sup>Medical ICU, Saint-Etienne University Hospital, Avenue Albert Raymond, 42270, Saint-Priest-en-Jarez, France; Jacques Lisfranc Faculty of Medicine, Jean Monnet University, 15 Rue Ambroise Paré, 42023, Saint-Etienne, France  
Full list of author information is available at the end of the article

142 mmol per liter [9] whereas abnormal serum concentration are usually defined as serum sodium lower than 135 or higher than 145 mmol per liter [2]. Most of the studies performed to date chose to focus on severe dysnatremia [1,5,7,10]. Recently, Funk and colleagues demonstrated influence of dysnatremia at ICU admission to be independently associated with outcome [2]. In this study, mild dysnatremia was independently associated with a poor outcome [2]. In addition, the association between serum sodium concentration and prognosis followed a U shape [2]. According to this observation, we hypothesized that borderline and mild changes in serum sodium concentration, lower than changes that usually alert physicians, should be taken into account.

The objective of this study was to assess the prevalence of dysnatremia, including borderline changes in serum sodium concentration in a large multicenter cohort of patients and to confirm the association of mild or moderate abnormal serum sodium concentration with mortality.

## Materials and methods

### Study design and data source

We conducted a retrospective study on a prospective multicenter database (OutcomeRea™) to assess the epidemiological characteristics and prognostic impact of dysnatremia. This study was approved by our institutional review board (CECIC Clermont-Ferrand - IRB number 5891; Ref: 2007-16) according to the French regulation on non-interventional studies which waived the need for signed informed consent for patients included in this database. Patients and patients' next of kin were, however, consulted for their willingness to decline participation to this database, and none refused to participate. The database, fed by 13 French ICUs, collects prospective data on daily disease severity, iatrogenic events, and nosocomial infections. Each year, each ICU includes a random sample of at least 50 patients who have ICU stays longer than 24 h. Each ICU could choose to obtain the random sample by taking either consecutive admissions to selected ICU beds throughout the year or consecutive admissions to all ICU beds for 1 month.

### Study population and definitions

We included consecutive patients who met the following criteria: age older than 18 years, entry in the database between January 1997 and April 2011. Patients without serum sodium measurement at ICU admission or with ICU stay of less than 48 h were secondarily excluded from the study.

Serum sodium concentration is reported at ICU admission.

We defined normal serum sodium concentration as a serum sodium level between 138 and 142 mmol/L [9].

Borderline dysnatremia were defined as serum sodium concentration between 135 and 137 mmol/L and between 143 and 145 mmol/L for borderline hyponatremia and for borderline hypernatremia respectively.

Hyponatremia were defined as serum sodium concentration  $< 135$  and  $\geq 130$ ,  $< 130$  and  $\geq 125$  or  $< 125$  for mild, moderate and severe hyponatremia respectively [6].

Hypernatremia were defined as serum sodium concentration  $> 145$  and  $\leq 150$ ,  $> 150$  and  $\leq 155$  or  $> 155$  for mild, moderate and severe hypernatremia respectively [6].

### Data collection

Data were collected daily by senior physicians and/or specifically trained study monitors in the participating ICUs. For each patient, the investigators entered the data into a computer case-report form using data-capture software (RHEA; OutcomeRea™, France) and imported all records into the OutcomeRea™ database. All codes and definitions were established prior to study initiation. The data quality checking procedure has been already described elsewhere [11]. The following information was recorded: age and sex, admission category (medical, scheduled surgery, or unscheduled surgery), origin (home, ward, or emergency department). Severity of illness was evaluated on the first ICU day using the Simplified Acute Physiology Score (SAPS) II, Sequential Organ Failure Assessment (SOFA) score and the Logistic Organ Dysfunction (LOD) score [12-14]. Knaus scale definitions were used to record preexisting chronic organ failures including respiratory, cardiac, hepatic, renal, and immune system failure [15].

### Quality of the database

For most of the study variables, the data-capture software immediately ran an automatic check for internal consistency, generating queries that were sent to the ICUs for resolution before incorporation of the new data into the database. In each participating ICU, data quality was checked by having a senior physician from another participating ICU review a 2% random sample of the study data every other year. A 1-day data-capture training course held once a year was open to all the OutcomeRea™ investigators and study monitors. All qualitative variables used in the analyses had  $\kappa$  coefficients  $> 0.8$  and all variables had inter-rater coefficients in the 0.67 to 1 range, indicating good to excellent reproducibility.

### Statistical analysis

Values of categorical variables are reported as numbers (%) and values of continuous variables as medians (inter-quartile range, IQR). The chi-square test was used for categorical data and the Wilcoxon test for continuous data.

Potential risk factors for dysnatremia were entered in a Fine and Gray extension of a Cox model. Then, we

used the Fine and Gray subdistribution hazard regression model [16], with day-30 mortality as the variable of interest. Discharge alive from the ICU was handled as a competing event. Subdistribution hazard ratios (sHR) and 95% confidence intervals (95% CI) were calculated.

*P* values < 0.05 were considered significant. Analyses were performed using SAS 9.1 software (SAS Institute; Cary, NC, USA).

## Results

### Study population

Of the 11,772 patients with ICU stays longer than 48 h who were entered into the database during the study period, 647 (5.5%) were excluded because of missing data (Figure 1). A total of 11,125 patients were included in this study. Some 3,047 (27.38%) had mild to severe hyponatremia at ICU admission, 2,258 (20.30%) had borderline hyponatremia at ICU admission, 1,078 (9.69%) had borderline hypernatremia and 877 (7.88%) had mild to severe hypernatremia (Figure 1). Among patients with mild to severe hyponatremia, 2,005 (18.02% of overall population) had mild hyponatremia, 693 (6.23% of overall population) had moderate hyponatremia, and 349 (3.14% of overall population) had severe hyponatremia. Among patients with mild to severe hypernatremia, 633 (5.69% of overall population) had mild hypernatremia, 143 (1.29% of overall population) had moderate hypernatremia, and 101 (0.91%) had severe hypernatremia (Figure 1 and Additional file 1,


Figure S1). Serum sodium value at ICU admission is reported in Figure 2.

### Characteristics of patients


Characteristics of patients at ICU admission are reported in Table 1. Overall, patients with dysnatremia were older, less frequently of male gender, had a higher body weight at ICU admission, a greater disease severity as assessed by SAPS II, SOFA score, organ failure at ICU admission or need for supportive therapy. In addition, patients with dysnatremia had more frequently underlying chronic illnesses.

### Outcome of patients with hypernatremia at ICU admission

Before adjustment, mortality at day 30 was 21.0% in the overall population of patients. Crude hospital mortality was increased in patients with borderline to severe hypernatremia and in patients with borderline to severe hyponatremia (Figure 1 and 3). Day-30 mortality was of 16.6% in patients without dysnatremia at ICU admission, 19.0% in patients with borderline hyponatremia, 22.2% in patients with mild hyponatremia, 26.4% in patients with moderate hyponatremia and 23.8% in patients with severe hyponatremia (Table 1 and Figure 3). Day-30 mortality was 22.5% in patients with borderline hypernatremia, 32.1% in patients with mild hypernatremia, 39.9% in patients with moderate hypernatremia and 54.5% in patients with severe hypernatremia. Cumulated







**Figure 2** Natremia distribution at ICU admission.

incidence of mortality according to serum sodium concentration at ICU admission is reported in Additional file 1, Figure S2a (hyponatremia) and Additional file 1, Figure S2b (hypernatremia). Relationship between serum sodium concentration and day-30 mortality is reported in Additional file 1, Figure S3.

When entered into a Fine and Gray model (Table 2), moderate to severe hyponatremia (sHR 1.82, 95% CI 1.002 to 1.395 and sHR 1.27, 95% CI 1.01 to 1.60 for moderate and severe hyponatremia respectively) and mild to severe hypernatremia (sHR 1.34, 95% CI 1.14 to 1.57; sHR 1.51, 95% CI 1.15 to 1.99; and sHR 2.64, 95% CI 2.00 to 3.81 for mild, moderate and severe hypernatremia respectively) remained independently associated with day-30 mortality. Borderline hyponatremia (sHR 1.09, 95% CI 0.97 to 1.23;  $P = 0.15$ ) and borderline hypernatremia (sHR 1.14, 95% CI 0.99 to 1.33;  $P = 0.08$ ) were not associated with day-30 mortality after adjustment for confounders. Figure 3 reports adjusted association between different class of dysnatremia and day-30 mortality before and after adjustment.

## Discussion

This large multicenter cohort study, focusing specifically on dysnatremia at ICU admission, demonstrates that this electrolyte disorder is common and is an independent risk factor for ICU mortality. This study confirms that mild hypernatremia and moderate hyponatremia (that is serum sodium concentration  $< 130$  mmol/L or  $> 145$  mmol/L respectively) are independently associated with poor outcome.


In this study, one-third of critically ill patients had a moderate to severe dysnatremia at ICU. Mild to severe hypernatremia and hyponatremia were present in respectively 7.8% and 27.4% of the admitted patients. Hyponatremia is the most common electrolyte disorder in hospitalized patients. Up to 40% of the overall population of hospitalized patients has a hyponatremia at admission [17]. Presence of severe hyponatremia on hospital admission has been demonstrated to be independently associated with an increased risk for ICU admission and poor prognosis [18]. Hyponatremia may be due to chronic organ dysfunctions (that is heart failure or liver dysfunction) but also to diuretic use, syndrome of inappropriate antidiuretic hormone (ADH) secretion, adrenal insufficiency, and cerebral or renal salt wasting syndromes [9,19]. Each of these conditions is frequently encountered in critically ill patients and may explain the high prevalence of hyponatremia at ICU admission. Similarly, although less frequent than hyponatremia, several studies demonstrated hypernatremia to be common at ICU admission [4-7]. Since thirst and free access to water are the most important mechanisms that prevent hypernatremia, critically ill patients and older patients are at high risk for this disorder [4,19]. Only 2.5% patients have been found to develop moderate to severe hypernatremia in the general in-hospital population of patients. Higher prevalence has been reported in geriatric or critically ill patients [20-23].

In keeping with previous findings, our study demonstrates a close association between dysnatremia and hospital mortality [1-3,8,13,24]. After adjustment for patients'

**Table 1 Characteristics of patients.**

	Severe hypoNa Na < 125 N = 349	Moderate hypoNa 125 ≤ Na < 130 N = 693	Mild hypoNa 130 ≤ Na < 135 N = 2005	Borderline hypoNa 135 ≤ Na < 138 N = 2258	No dysnatremia 138-142 N = 3865	Borderline hyperNa 142 > Na ≥ 145 N = 1078	Mild hyperNa 145 > Na ≥ 150 N = 633	Moderate hyperNa 150 > Na ≥ 155 N = 143	Severe hyperNa Na > 155 N = 101	P value*
<b>Patient characteristics</b>										
Male gender	197 (56.4%)	392 (56.6%)	1211 (60.4%)	1381 (61.2%)	2391 (61.9%)	649 (60.2%)	380 (60%)	81 (56.6%)	60 (59.4%)	0.1846
Age (yrs)	62 (51-75)	63 (49.5-75.5)	63 (51-76)	62 (49-75)	63 (49-76)	62 (48-75)	65 (53-76)	67 (46-77)	64 (57-77)	0.0358
Weight (kg)	67 (56-80)	69 (58-81)	68 (58.4-80)	71 (60-83)	70.3 (60-83)	70 (60-82)	70 (59.7-81)	65 (59.7-80)	69 (55-80)	< .0001
SOFA score [13]	6 (3-8)	6 (4-9)	5 (3-8)	5 (3-7)	5 (2-7)	5 (3-9)	7 (4-10)	8 (5-11)	8 (6-12)	< .0001
SAPS II score [14]	56 (45-66)	57 (47-66)	55 (44-65)	51 (41-61)	50 (39-60)	53 (43-65)	57 (47-69)	63 (52-73)	66 (54-78)	< .0001
<b>Underlying condition</b>										
Chronic kidney disease	20 (5.7%)	50 (7.2%)	142 (7.1%)	121 (5.4%)	225 (5.8%)	61 (5.7%)	30 (4.7%)	7 (4.9%)	4 (4%)	0.2031
Immunocompromised	55 (15.8%)	143 (20.6%)	366 (18.3%)	343 (15.2%)	458 (11.8%)	128 (11.9%)	93 (14.7%)	12 (8.4%)	12 (11.9%)	< .0001
<b>Main symptom at admission</b>										
Acute respiratory failure	65 (18.6%)	189 (27.3%)	529 (26.4%)	580 (25.7%)	893 (23.1%)	244 (22.6%)	151 (23.9%)	21 (14.7%)	20 (19.8%)	0.0003
Coma	68 (19.5%)	74 (10.7%)	216 (10.8%)	296 (13.1%)	661 (17.1%)	236 (21.9%)	138 (21.8%)	51 (35.7%)	28 (27.7%)	< .0001
Septic shock	33 (9.5%)	98 (14.1%)	294 (14.7%)	225 (10%)	343 (8.9%)	107 (9.9%)	76 (12%)	18 (12.6%)	9 (8.9%)	< .0001
Shock (other)	42 (12%)	86 (12.4%)	226 (11.3%)	218 (9.7%)	327 (8.5%)	122 (11.3%)	84 (13.3%)	16 (11.2%)	16 (15.8%)	< .0001
Acute renal failure	47 (13.5%)	78 (11.3%)	128 (6.4%)	101 (4.5%)	108 (2.8%)	39 (3.6%)	25 (3.9%)	7 (4.9%)	7 (6.9%)	< .0001
Trauma	0	1 (0.1%)	13 (0.6%)	19 (0.8%)	66 (1.7%)	11 (1%)	6 (0.9%)	5 (3.5%)	1 (1%)	< .0001
<b>Treatments at ICU admission</b>										
Antibiotics	190 (54.4%)	446 (64.4%)	1278 (63.7%)	1236 (54.7%)	1903 (49.2%)	567 (52.6%)	387 (61.1%)	90 (62.9%)	75 (74.3%)	< .0001
Central venous catheter	125 (35.8%)	312 (45%)	824 (41.1%)	867 (38.4%)	1446 (37.4%)	459 (42.6%)	342 (54%)	79 (55.2%)	60 (59.4%)	< .0001
Vasoactive drugs	107 (30.7%)	259 (37.4%)	671 (33.5%)	650 (28.8%)	1041 (26.9%)	350 (32.5%)	277 (43.8%)	65 (45.5%)	49 (48.5%)	< .0001
Mechanical ventilation	124 (35.5%)	253 (36.5%)	840 (41.9%)	1026 (45.4%)	1846 (47.8%)	605 (56.1%)	363 (57.3%)	93 (65%)	62 (61.4%)	< .0001
Renal replacement therapy	53 (15.2%)	113 (16.3%)	212 (10.6%)	217 (9.6%)	307 (7.9%)	96 (8.9%)	83 (13.1%)	11 (7.7%)	19 (18.8%)	< .0001
<b>Outcome</b>										
DFLST	16 (4.6%)	49 (7.1%)	108 (5.4%)	93 (4.1%)	171 (4.4%)	78 (7.2%)	51 (8.1%)	11 (7.7%)	7 (6.9%)	< .0001
ICU mortality	66 (18.9%)	160 (23.1%)	381 (19%)	360 (15.9%)	551 (14.3%)	220 (20.4%)	176 (27.8%)	48 (33.6%)	49 (48.5%)	< .0001
Day-30 mortality	83 (23.8%)	183 (26.4%)	446 (22.2%)	430 (19.0%)	642 (16.6%)	242 (22.5%)	203 (32.1%)	57 (39.9%)	55 (54.5%)	< 0.001
Hospital mortality	89 (25.5%)	201 (29.0%)	483 (24.1%)	458 (20.3%)	693 (17.9%)	264 (24.5%)	215 (34.0%)	58 (40.6%)	57 (56.4%)	< .0001

\*Comparison across different subclasses of serum sodium concentration at ICU admission. The data are reported as medians (IQR). SOFA, Sequential Organ Failure Assessment, which can range from 0 to 24; SAPS II, Simplified Acute Physiology Score version II, which can range from 0 to 155; DFLST, decision to forgo life-sustaining treatments.



severity, increasing degree of dysnatremia was associated with increasing prognostic impact. Interestingly, our study demonstrates that mild to severe hypernatremia and moderate to severe hyponatremia are independently associated with outcome. Earlier studies reported an association between dysnatremia and hospital mortality [1-3,10]. However, most of these studies evaluated the more severe patients [1-3,10]. Recent studies suggested mild to moderate changes in serum sodium concentration to be associated with prognosis [2,24]. In our study, after adjustment for comorbidities, case mix, or patients' severity, even mild hypernatremia and moderate hyponatremia were independently associated with poor outcome. Hypernatremia has multiple adverse effects that may explain this association. Hypernatremia has been shown to be associated with peripheral insulin resistance, impaired hepatic lactate clearance, decreased left ventricular contractility or various neuromuscular manifestations ranging from muscle weakness to delayed weaning from mechanical ventilation [25-28]. Similarly, hyponatremia may be associated with dismal neurological manifestations although occurring in

profound hyponatremia [9,19]. Our study, however, was not designed to evaluate these consequences and no causality relationship can be drawn from this association. Last, our study was unable to demonstrate an association between outcome and borderline changes in natremia or mild hyponatremia. Nevertheless, progressive association between serum sodium changes and hospital mortality suggest that we should pay attention to mild abnormal serum sodium concentration.

Our study has several limitations. First, our study design did not allow us to evaluate the causes of dysnatremia. No data regarding fluid balance or diuretic therapy before ICU admission were available. In addition, as previously stated, our study was not designed to evaluate factors leading to this association. Although a causal role for dysnatremia in death is biologically plausible, we cannot determine from our data whether the association between dysnatremia and mortality reflected a direct effect of dysnatremia, a surrogate marker for underlying comorbidities or reason for ICU admission, or both. Further studies evaluating the influence of dysnatremia



**Table 2 Factors independently associated with day-30 mortality.**

	sHR	95% CI	P value
<b>Natremia</b>			
Severe hyponatremia	1.27	(1.01-1.60)	0.040
Moderate hyponatremia	1.18	(1.002-1.40)	0.047
Mild hyponatremia	1.08	(0.95-1.22)	0.23
Borderline hyponatremia	1.09	(0.97-1.24)	0.15
Normal natremia	1	(Ref)	-
Borderline hypernatremia	1.09	(0.97-1.24)	0.15
Mild hypernatremia	1.34	(1.14-1.57)	0.0003
Moderate hypernatremia	1.51	(1.15-1.99)	0.003
Severe hypernatremia	2.64	(2.00-3.48)	< 0.0001
DFLST*	3.24	(2.90-3.62)	< 0.0001
Intoxication as reason for ICU admission	0.21	(0.13-0.34)	< 0.0001
Chronic cardiac dysfunction	1.26	(1.13-1.41)	< 0.0001
Immunocompromised patient	1.30	(1.17-1.45)	< 0.0001
Age > 64 yrs	1.56	(1.43-1.71)	< 0.0001
SOFA score (per point)*	1.21	(1.20-1.23)	< 0.0001

(Subdistribution hazard ratios (sHR) and 95% confidence intervals (95% CI)).  
\*DFLST, decision to forgo life-sustaining treatments; SOFA, Sequential Organ Failure Assessment, which can range from 0 to 24.

correction on prognosis or the influence of therapeutic intervention in patients with mild to moderate dysnatremia may help in answering this clinical question.

## Conclusions

Our results confirm the high prevalence of dysnatremia at ICU admission and demonstrate that even mild to moderate abnormal serum sodium concentrations are independent risk factors for ICU mortality. Although we must acknowledge that dysnatremia may be a surrogate for patients' severity, treatment or case mix, we believe that mild abnormal serum sodium concentration should not be neglected. Further studies are needed to understand factors leading to this prognostic association and the potential benefit from therapeutic strategies aiming at this metabolic disturbance.

## Key messages

- Dysnatremia is common at ICU admission. Mild to severe hypernatremia and hyponatremia were present in respectively 7.8% and 27.4% of the critically ill patients.
- Dysnatremia is independently associated with ICU mortality. In our study, mild hypernatremia (that is serum sodium concentration > 145 mmol/L) and moderate hyponatremia (that is serum sodium concentration < 130 mmol/L) are independently associated with poor outcome (respective sHR of 1.34 (95% CI 1.14 to 1.57) and 1.18 (95% CI 1.002 to 1.40)).

- Although a causal role for dysnatremia in death is biologically plausible, we cannot determine from our data whether the association between dysnatremia and mortality reflected a direct effect of dysnatremia, a surrogate marker for underlying comorbidities or reason for ICU admission, or both.

## Additional material

**Additional file 1: Additional figures and members of the Outcomerea study group.** **Figure S1:** Frequency of dysnatremia for each of the evaluated subgroups. **Figure S2:** Cumulative incidence (Y) for mortality according to serum sodium concentration at ICU admission in patients with hyponatremia (**2a**) and hypernatremia (**2b**). **Figure S3.** Relationship between hospital admission serum sodium concentrations and day-30 mortality. **Appendix A:** Members of the Outcomerea study group.

## Abbreviations

95% CI: 95% confidence interval; ICU: intensive care unit; SAPS II: Simplified Acute Physiology Score version II; sHR: subdistribution hazard ratio; SOFA: Sequential Organ Failure Assessment.

## Authors' contributions

Prof Darmon and Prof Timsit had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MD participated in the study concept and design, the acquisition of data, the interpretation of the data, and the drafting of the manuscript. ED participated in the study design, the acquisition of the data and critical revisions of the manuscript. BS participated in the study design, the acquisition of the data and critical revisions of the manuscript. SR participated in the statistical analysis and critical revision of the manuscript. CA, EA, CC, MGO, CS, DGT, HK, ASD, SJ, CCh and BA participated in the acquisition of the data, interpretation of the results and critical revisions of the manuscript. FZ participated in the study design, the acquisition of the data and critical revisions of the manuscript. JFT participated in the study design, acquisition of data, statistical analysis, interpretation of the data, and drafting of the manuscript. The final version of the manuscript was read and approved by all of the authors.

## Competing interests

The authors have no competing interests to declare.

## Acknowledgements

We thank A. Wolfe MD for helping with this manuscript. This study was performed on the behalf of the Outcomerea™ study group.

## Author details

<sup>1</sup>Medical ICU, Saint-Etienne University Hospital, Avenue Albert Raymond, 42270, Saint-Priest-en-Jarez, France; Jacques Lisfranc Faculty of Medicine, Jean Monnet University, 15 Rue Ambroise Paré, 42023, Saint-Etienne, France. <sup>2</sup>Medical ICU, Gabriel Montpied University Hospital, 58 Rue Montalembert, 63003, Clermont-Ferrand Cedex 1, France. <sup>3</sup>University of Grenoble 1 (Joseph Fourier) Integrated Research Center U 823 - Albert Bonniot Institute, Grenoble University Hospital, Rond Point de la Chantourne, 38706, La Tronche, Grenoble, France. <sup>4</sup>Polyvalent ICU, Grenoble University Hospital, Pavillon Dauphine, BP217, 38043, Grenoble Cedex 9, France. <sup>5</sup>Department of Physiology, Cochin University Hospital, APHP, 27 Rue du Faubourg St Jacques, 75014, Paris, France. <sup>6</sup>Medical ICU, St Louis University Hospital, 1 Avenue Claude Vellefaux, 75010, Paris, France. <sup>7</sup>Medical-Surgical ICU, Avicenne University Hospital, 125 Rue de Stalingrad, 93000, Bobigny, France; Paris-13 University, 93000, Bobigny, France. <sup>8</sup>Polyvalent ICU, Groupe Hospitalier St Joseph, 145 Rue Raymond Losserand, 75014, Paris, France. <sup>9</sup>Polyvalent ICU, Gonesse General Hospital, 25 Rue Bernard Fevrier, 95500, Gonesse, France. <sup>10</sup>Intensive Care Unit, Centre Hospitalier Andrée Rosemon,

Avenue des Flamboyants, 97306, Cayenne, France. <sup>11</sup>Surgical ICU, Antoine Bécère University Hospital, 157 Rue de la Porte de Trivaux, 92141, Clamart Cedex, France. <sup>12</sup>Polyvalent ICU, Centre Hospitalier Sud Essonne Dourdan-Etampes-Siège, 26 Avenue Charles de Gaulle, 91150, Etampes, France. <sup>13</sup>Medical-Surgical ICU, Hyeres Hospital, Rue du Maréchal Juin, 83407, Hyeres, France. <sup>14</sup>Surgical ICU, Edouard Herriot University Hospital, Hospices Civiles de Lyon, 5 Place Arsonval, 69437, Lyon, France.

Received: 24 August 2012 Revised: 12 December 2012  
Accepted: 11 January 2013 Published: 21 January 2013

## References

- Bennani S-L, Abouqal R, Zeggwagh A-A, Madani N, Abidi K, Zekraoui A, Kerkeb O: [Incidence, causes and prognostic factors of hyponatremia in intensive care]. *Rev Med Interne* 2003, **24**:224-229.
- Funk G-C, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, Metnitz PGH: Incidence and prognosis of dysnatremias present on ICU admission. *Intensive Care Med* 2010, **36**:304-311.
- Lindner G, Funk G-C, Schwarz C, Kneidinger N, Kaider A, Schneeweiss B, Kramer L, Druml W: Hypertatremia in the critically ill is an independent risk factor for mortality. *Am J Kidney Dis* 2007, **50**:952-957.
- Hoon EJ, Betjes MGH, Weigel J, Zietse R: Hypertatremia in critically ill patients: too little water and too much salt. *Nephrol Dial Transplant* 2008, **23**:1562-1568.
- Lindner G, Kneidinger N, Holzinger U, Druml W, Schwarz C: Tonicity balance in patients with hypertatremia acquired in the intensive care unit. *Am J Kidney Dis* 2009, **54**:674-679.
- Darmon M, Timsit J-F, Francois A, Nguile-Makao M, Adrie C, Cohen Y, Garrouste-Orgeas M, Goldgran-Toledano D, Dumenil A-S, Jamali S, Cheval C, Allaouchiche B, Souweine B, Azoulay E: Association between hypertatremia acquired in the ICU and mortality: a cohort study. *Nephrol Dial Transplant* 2010, **25**:2510-2515.
- Stelfox HT, Ahmed SB, Zygun D, Khandwala F, Laupland K: Characterization of intensive care unit acquired hyponatremia and hypertatremia following cardiac surgery. *Can J Anaesth* 2010, **57**:650-658.
- Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K: The epidemiology of intensive care unit-acquired hyponatremia and hypertatremia in medical-surgical intensive care units. *Crit Care* 2008, **12**:R162.
- Kumar S, Berl T: Sodium. *Lancet* 1998, **352**:220-228.
- Polderman KH, Schreuder WO, Strack van Schijndel RJ, Thijs LG: Hypertatremia in the intensive care unit: an indicator of quality of care? *Crit Care Med* 1999, **27**:1105-1108.
- Laupland KB, Zahar J-R, Adrie C, Minet C, Vésin A, Goldgran-Toledano D, Azoulay E, Garrouste-Orgeas M, Cohen Y, Schwebel C, Jamali S, Darmon M, Dumenil A-S, Kallel H, Souweine B, Timsit J-F: Severe hypothermia increases the risk for intensive care unit-acquired infection. *Clin Infect Dis* 2012, **54**:1064-70.
- Timsit J-F, Fosse J-P, Troché G, De Lassence A, Alberti C, Garrouste-Orgeas M, Bornstein C, Adrie C, Cheval C, Chevret S: Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. *Crit Care Med* 2002, **30**:2003-2013.
- Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA* 1993, **270**:2957-2963.
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 1996, **22**:707-710.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. *Crit Care Med* 1985, **13**:818-829.
- Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M: Modeling the effect of time-dependent exposure on intensive care unit mortality. *Intensive Care Med* 2009, **35**:826-832.
- Sedlacek M, Schoolwerth AC, Remillard BD: Electrolyte disturbances in the intensive care unit. *Semin Dial* 2006, **19**:496-501.
- Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, Colby C, Shorr AF: Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. *Curr Med Res Opin* 2008, **24**:1601-1608.
- Adrogué HJ, Madias NE: Hypertatremia. *N Engl J Med* 2000, **342**:1581-1589.
- Macdonald NJ, McConnell KN, Stephen MR, Dunnigan MG: Hypertatremic dehydration in patients in a large hospital for the mentally handicapped. *BMJ* 1989, **299**:1426-1429.
- Palevsky PM, Bhargava R, Greenberg A: Hypertatremia in hospitalized patients. *Ann Intern Med* 1996, **124**:197-203.
- Long CA, Marin P, Bayer AJ, Shetty HG, Pathy MS: Hypertatremia in an adult in-patient population. *Postgrad Med J* 1991, **67**:643-645.
- Borra SI, Beredo R, Kleinfeld M: Hypertatremia in the aging: causes, manifestations, and outcome. *J Natl Med Assoc* 1995, **87**:220-224.
- Lindner G, Funk G-C, Lassnigg A, Mouhieddine M, Ahmad S-A, Schwarz C, Hiesmayr M: Intensive care-acquired hypertatremia after major cardiothoracic surgery is associated with increased mortality. *Intensive Care Med* 2010, **36**:1718-1723.
- Adrogué HJ, Madias NE: Hypertatremia. *N Engl J Med* 2000, **342**:1493-1499.
- Lenz K, Gössinger H, Laggner A, Druml W, Grimm G, Schneeweiss B: Influence of hypertatremic-hyperosmolar state on hemodynamics of patients with normal and depressed myocardial function. *Crit Care Med* 1986, **14**:913-914.
- Bratusch-Marrain PR, DeFronzo RA: Impairment of insulin-mediated glucose metabolism by hyperosmolality in man. *Diabetes* 1983, **32**:1028-1034.
- Kozény GA, Murdock DK, Euler DE, Hano JE, Scanlon PJ, Bansal VK, Vertuno LL: In vivo effects of acute changes in osmolality and sodium concentration on myocardial contractility. *Am Heart J* 1985, **109**:290-296.

doi:10.1186/cc11937

Cite this article as: Darmon *et al.*: Prognostic consequences of borderline dysnatremia: pay attention to minimal serum sodium change. *Critical Care* 2013 **17**:R12.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

